United Therapeutics Corporation (UTHR)UTHRUnited Therapeutics Corporation

Financials

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	3.17B	781.50M	790.20M	799.50M	798.60M	794.40M	735.90M	748.90M	714.90M
Cost of Goods Sold	425.30M	133.40M	103.40M	100.90M	87.60M	92.50M	75.90M	83.10M	77.80M
Gross Profit	2.74B	648.10M	686.80M	698.60M	711.00M	701.90M	660.00M	665.80M	637.10M
Gross Profit Margin	86.6%	82.9%	86.9%	87.4%	89.0%	88.4%	89.7%	88.9%	89.1%
Total Operating Expenses	1.31B	322.30M	329.30M	309.30M	346.50M	319.10M	302.30M	322.70M	317.20M
Research & Development	539.20M	138.20M	139.50M	127.50M	134.00M	149.00M	133.80M	103.50M	139.60M
Selling, General & Administrative	746.50M	184.10M	189.80M	181.80M	190.80M	170.10M	162.50M	219.20M	177.60M
Operating Income (EBIT)	1.44B	325.80M	357.50M	389.30M	364.50M	382.80M	357.70M	343.10M	319.90M
Operating Margin	45.3%	41.7%	45.2%	48.7%	45.6%	48.2%	48.6%	45.8%	44.7%
Income Before Tax (EBT)	1.61B	318.30M	444.00M	438.00M	408.40M	423.50M	396.50M	388.60M	355.30M
Interest Income	182.70M	41.80M	43.20M	46.40M	51.30M	51.10M	49.30M	49.80M	46.20M
Interest Expense	16.40M	3.00M	3.10M	3.00M	7.30M	6.10M	7.90M	10.10M	11.60M
Other Income/Expense	171.60M	-7.50M	86.50M	48.70M	43.90M	40.70M	38.80M	45.50M	35.40M
Net Income	1.29B	274.90M	364.30M	338.70M	309.50M	322.20M	301.30M	309.10M	278.10M
Income Tax Expense	321.30M	43.40M	79.70M	99.30M	98.90M	101.30M	95.20M	79.50M	77.20M
Net Profit Margin	40.6%	35.2%	46.1%	42.4%	38.8%	40.6%	40.9%	41.3%	38.9%
EBITDA	1.53B	348.40M	380.30M	411.20M	385.60M	402.60M	377.40M	362.20M	338.60M
EBITDA Margin	48.1%	44.6%	48.1%	51.4%	48.3%	50.7%	51.3%	48.4%	47.4%
Depreciation & Amortization	88.40M	22.60M	22.80M	21.90M	21.10M	19.80M	19.70M	19.10M	18.70M
EPS Basic	29.27	6.32	8.36	7.73	6.86	7.18	6.74	6.93	6.26
EPS Diluted	27.05	5.82	7.66	7.16	6.41	6.63	6.19	6.39	5.85
Shares Outstanding	43.50M	43.50M	44.30M	43.80M	45.10M	44.90M	45.20M	44.60M	44.40M
Diluted Shares Outstanding	47.20M	47.20M	47.90M	47.30M	48.30M	48.60M	48.70M	48.40M	47.50M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	3.18B	2.88B	2.33B	1.94B	1.69B	1.48B	1.45B	1.63B
Cost of Goods Sold	384.40M	309.70M	257.50M	146.70M	122.50M	108.10M	117.60M	198.70M
Gross Profit	2.80B	2.57B	2.07B	1.79B	1.56B	1.38B	1.33B	1.43B
Gross Profit Margin	87.9%	89.2%	88.9%	92.4%	92.7%	92.7%	91.9%	87.8%
Total Operating Expenses	1.28B	1.19B	885.10M	809.90M	1.01B	781.60M	1.52B	623.70M
Research & Development	550.00M	481.00M	408.00M	322.90M	540.10M	357.70M	1.18B	357.90M
Selling, General & Administrative	731.10M	638.60M	477.10M	487.00M	467.00M	423.90M	336.20M	265.80M
Operating Income (EBIT)	1.52B	1.38B	1.18B	979.70M	555.90M	593.60M	-187.60M	805.40M
Operating Margin	47.7%	47.9%	50.9%	50.6%	33.0%	40.0%	-12.9%	49.5%
Income Before Tax (EBT)	1.71B	1.54B	1.27B	950.60M	593.90M	638.90M	-165.00M	758.90M
Interest Income	192.00M	199.10M	162.70M	45.20M	16.70M	28.60M	44.20M	28.60M
Interest Expense	19.50M	42.90M	59.30M	32.40M	18.60M	23.50M	44.20M	13.90M
Other Income/Expense	196.70M	162.00M	89.40M	-29.10M	38.00M	45.30M	22.60M	-46.50M
Net Income	1.33B	1.20B	984.80M	727.30M	475.80M	514.80M	-104.50M	589.20M
Income Tax Expense	379.20M	343.90M	289.50M	223.30M	118.10M	124.10M	-60.50M	169.70M
Net Profit Margin	41.9%	41.5%	42.3%	37.6%	28.2%	34.7%	-7.2%	36.2%
EBITDA	1.60B	1.45B	1.24B	1.03B	605.80M	643.50M	-141.70M	841.30M
EBITDA Margin	50.4%	50.4%	53.2%	53.2%	35.9%	43.4%	-9.8%	51.7%
Depreciation & Amortization	85.60M	72.50M	53.20M	51.30M	49.90M	49.90M	45.90M	35.90M
EPS Basic	30.13	26.44	21.04	15.98	10.60	11.65	-2.39	13.54
EPS Diluted	27.86	24.64	19.81	15.00	10.06	11.54	-2.39	13.39
Shares Outstanding	44.30M	45.20M	46.80M	45.50M	44.90M	44.20M	43.80M	43.50M
Diluted Shares Outstanding	47.90M	48.50M	49.70M	48.50M	47.30M	44.60M	43.80M	44.00M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.

About United Therapeutics Corporation

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both the United States and international markets. The company's current commercial portfolio features several key therapeutics: Remodulin, prescribed for pulmonary arterial hypertension (PAH) to lessen symptoms experienced during physical activity. Tyvaso, an inhaled form of the prostacyclin analogue treprostinil, designed to enhance exercise capacity in patients with PAH and pulmonary hypertension linked to interstitial lung disease (PH-ILD). Orenitram, a treprostinil tablet formulation, also aims to boost the exercise capabilities of PAH patients. Unituxin, a monoclonal antibody utilized in the treatment of high-risk neuroblastoma. Adcirca, an oral PDE-5 inhibitor, which helps improve exercise performance in those with PAH. United Therapeutics also maintains a robust development pipeline, including: Tyvaso DPI, a dry powder inhaler version of Tyvaso. The Remunity Pump, a compact, lightweight, and durable infusion system for treprostinil, accompanied by a separate controller. RemoPro and Ralinepag, both investigational treatments for PAH. Aurora-GT, a gene therapy product focused on regenerating blood vessels within the lungs. Clinical trials such as Tyvaso PERFECT and TETON, which are evaluating Tyvaso's efficacy in patients with World Health Organization (WHO) Group 3 pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD). The company has forged strategic alliances and licensing agreements with various entities, such as DEKA Research & Development Corp. for a semi-disposable subcutaneous treprostinil delivery system; MannKind Corporation for the development and licensing of treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. for the development of Ralinepag. Established in 1996, United Therapeutics Corporation is headquartered in Silver Spring, Maryland.

Silver Spring, MD

1,400 employees

www.unither.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Martine A. Rothblatt

View full financials